Preclinical Pharmacology of the Taxanes: Implications of the Differences
Open Access
- 2 June 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 9 (S2) , 3-8
- https://doi.org/10.1634/theoncologist.9-suppl_2-3
Abstract
Learning Objectives After completing this course, the reader will be able to: Identify the differences in molecular pharmacology of the taxanes. Describe the impact of the pharmacokinetic and pharm...Keywords
This publication has 15 references indexed in Scilit:
- Docetaxel for Patients With Paclitaxel-Resistant Müllerian CarcinomaJournal of Clinical Oncology, 2000
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy RegimensJournal of Clinical Oncology, 2000
- Docetaxel Administered on a Weekly Basis for Metastatic Breast CancerJournal of Clinical Oncology, 2000
- Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell DeathJournal of Clinical Oncology, 1999
- Clinical Pharmacokinetics of DocetaxelClinical Pharmacokinetics, 1999
- A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.Journal of Clinical Oncology, 1998
- Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.Journal of Clinical Oncology, 1998
- S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cellsBritish Journal of Cancer, 1995
- Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.Journal of Clinical Oncology, 1995
- Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cellsAnti-Cancer Drugs, 1992